Core Viewpoint - The domestic market for sleep breathing machines is still a blue ocean, with leading companies like Ruimai Te and Yuyue Medical showing significant strength in this niche sector [1][3][17]. Group 1: Market Overview - The market for sleep breathing machines is expanding due to increasing awareness of sleep-related health issues, particularly obstructive sleep apnea (OSA) [1][3]. - Ruimai Te ranks first in China and second globally in market share for home breathing machines, indicating strong competitive positioning [3][17]. - The company has seen a surge in consumer interest, with nearly half of the population starting to explore and purchase these devices online [3][17]. Group 2: Company Performance - Ruimai Te's stock price has increased by approximately 29% in 2025, reversing a three-year decline, with a peak above 100 yuan before stabilizing around 80 yuan [4][18]. - The company reported a revenue of 2.66 billion yuan in Q1 2025, a 38.11% increase year-on-year, and a net profit of approximately 601.9 million yuan, up 44.11% [4][18]. - For the first nine months of 2025, Ruimai Te achieved a revenue of 5.21 billion yuan, a 39.07% increase, with consumables revenue growing by 27.26% [23]. Group 3: Product Innovation - Ruimai Te has introduced advanced home breathing machines equipped with a smart algorithm that can accurately identify various respiratory events and adjust pressure in real-time [24][25]. - The company’s G3X model has received FDA approval and is expected to meet the needs of high-end customers in North America, contributing to a 133.85% increase in revenue from the U.S. market [5][19]. - The smart algorithm enhances user experience by synchronizing with the user's breathing rhythm, providing a comfortable treatment experience [24][25]. Group 4: Competitive Landscape - Yuyue Medical is a key competitor in the market, offering various models of non-invasive breathing machines, including continuous positive airway pressure (CPAP) devices [11][27]. - Both companies are engaged in healthy competition, driving growth in the medical device sector, with a focus on product effectiveness and user comfort [28]. - The market is characterized by a growing number of manufacturers, but only Ruimai Te and Yuyue Medical are publicly listed, indicating a concentrated competitive environment [28].

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [8] - For the nine months ended September 30, 2025, revenue increased approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9] - Gross profit for Q3 2025 increased approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11] - Net loss increased to $5.4 million in Q3 2025 and $14.3 million for the first nine months of 2025 [12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada and $1.3 million from new treatment centers [8] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at Sleep Center of Nevada, indicating substantial growth potential [26] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [26] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and testing centers aims to increase patient access to Vivos technology and improve financial returns [20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is central to the new model, focusing on educating and evaluating patients for treatment [24] - Future initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups [32] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating the company's ability to monetize its technology for treating sleep-related disorders [17] - The company expects revenue growth to continue as new dental providers and nurse practitioners are onboarded, with a projected ramp-up period of three to six months for optimal revenue levels [42][44] - Management believes the new model is replicable and scalable across multiple markets, with a focus on achieving cash flow break-even in the near future [50][56] Other Important Information - The company has secured $14.2 million in net cash from financing activities, with total liabilities of $23.1 million and cash and cash equivalents of $3.1 million as of September 30, 2025 [13] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new providers are deployed, with a ramp-up period of three to six months for optimal revenue levels [41][44] Question: What are the reasonable operating expenses for the next quarter? - SAMHSA operations are expected to achieve contribution margins of 50%-60% at steady-state, with current expenses being higher due to upfront investments in personnel [46][47] Question: Update on cash flow break-even goals? - The goal is to achieve cash flow break-even, with expectations that profits from SAMHSA center operations will contribute to this goal in the near future [49][50] Question: How should investors view the company now and in six months? - Management believes the company has finally settled on a monetization model that leverages its technological advantages, with significant growth potential ahead [55][56]

Financial Data and Key Metrics Changes - For Q3 2025, revenue increased by 76% to $6.8 million compared to $3.9 million in Q3 2024, and 78% sequentially from Q2 2025 [7][9] - For the nine months ended September 30, 2025, revenue increased by approximately $2.3 million, or 20%, to $13.6 million compared to $11.3 million for the same period in 2024 [9][12] - Gross profit for Q3 2025 increased by approximately $1.6 million to $3.9 million, with gross margin slightly decreasing to 58% from 60% in Q3 2024 [11][12] Business Line Data and Key Metrics Changes - The increase in revenue was driven by a $2.2 million increase in OSA sleep testing services primarily from the Sleep Center of Nevada, and $1.3 million from new treatment centers [8][9] - VIP enrollment revenue from the legacy business model decreased by $800,000, indicating a shift towards the new business model [9][10] Market Data and Key Metrics Changes - The company is currently servicing significantly less than 40% of the potential new patients being tested each month at the Sleep Center of Nevada, indicating substantial growth potential [24] - Over 210,000 OSA patients have been tested and seen by SCN providers since 2019, with many legacy patients potentially seeking alternatives to CPAP [24] Company Strategy and Development Direction - The strategic pivot towards acquiring sleep medical practices and forming alliances is aimed at increasing market penetration and financial returns [19][20] - The establishment of Sleep and Airway Medicine Centers (SAMHSA Centers) is part of the strategy to educate and evaluate patients for treatment options [22][30] Management's Comments on Operating Environment and Future Outlook - Management views Q3 2025 as a watershed quarter, indicating a significant inflection point in the company's ability to monetize its technology for treating sleep-related disorders [16][19] - The company expects revenue growth to outpace expenses as new teams are deployed and operational efficiencies are realized [23][33] Other Important Information - The company has secured $14.2 million in net cash from financing activities, which will support its growth initiatives [13] - General and administrative expenses increased by approximately $5.7 million, primarily due to costs associated with the Sleep Center of Nevada operations [12] Q&A Session Summary Question: How should sales be modeled for the next few quarters? - Management expects top-line revenues to continue to grow as new dental providers and nurse practitioners are added to the teams [35] Question: What is the expected ramp-up time for revenue generation? - A ramp-up period of approximately three to six months is anticipated to reach optimized revenue levels [36] Question: What are the expected contribution margins for SAMHSA operations? - Steady-state operations are expected to yield contribution margins of 50%-60% [38] Question: What is the goal for cash flow break-even? - The goal is to achieve cash flow break-even, with ongoing efforts to manage growth and operational expenses [39] Question: How should investors view the company now and in six months? - Management believes the company has finally found a monetization model that aligns with its technological advantages, indicating strong future growth potential [41][42]